View More Recent Stories
-
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year
-
Sunshine Biopharma, Inc. (SBFM) Acquires Marketing Rights for Two New Antibiotics in Canada
-
Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada
-
Sunshine Biopharma, Inc. (SBFM) Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian Market
-
Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market
-
Sunshine Biopharma (SBFM) Expands Its Product Line to 69 Generic Prescription Drugs
-
Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT
-
Sunshine Biopharma, Inc. (SBFM) Appoints Michel Roy as Chief Commercial Officer
-
Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer
-
Sunshine Biopharma, Inc. (SBFM) Files $100M Mixed Shelf
-
Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus
-
Sunshine Biopharma SBFM) Launches a New Generic Prescription Drug
-
Sunshine Biopharma Launches a New Generic Prescription Drug
-
Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%
-
Sunshine Biopharma (SBFM) Launches Two New Generic Prescription Drugs
-
Sunshine Biopharma Launches Two New Generic Prescription Drugs
-
Sunshine Biopharma (SBFM) Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry
-
Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry
-
Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada
-
Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%
-
Sunshine Biopharma (SBFM) Announces Reverse Stock Split
-
Sunshine Biopharma Announces Reverse Stock Split
